Cullinan Therapeutics (CGEM) Depreciation & Amortization (CF) (2020 - 2026)
Cullinan Therapeutics (CGEM) posted quarterly Depreciation & Amortization (CF) of $79000.0 for Q1 2026, up 3.95% year-over-year from $76000.0 in Q1 2025, and little changed quarter-over-quarter from $79000.0 in Q4 2025.
Powered by 
Analysis
Cullinan Therapeutics (CGEM) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Cullinan Therapeutics' Depreciation & Amortization (CF) history runs 7 years deep, the most recent figure standing at $79000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 3.95% year-over-year to $79000.0; the TTM figure through Mar 2026 stood at $314000.0 (up 2.61% YoY), while the FY2025 annual figure was $311000.0, up 1.63% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $79000.0, roughly flat from $79000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $81000.0 in Q2 2023, with the low at $9000.0 in Q3 2022.
- The 5-year median for Depreciation & Amortization (CF) is $77000.0 (2023), against an average of $64647.1.
- The sharpest annual moves came in 2022 and 2023: Depreciation & Amortization (CF) sank 30.77% in 2022, then soared 788.89% in 2023.
- Cullinan Therapeutics' Depreciation & Amortization (CF) stood at $59000.0 in 2022, then surged by 30.51% to $77000.0 in 2023, then changed by 0.0% to $77000.0 in 2024, then rose by 2.6% to $79000.0 in 2025, then changed by 0.0% to $79000.0 in 2026.
- Business Quant data shows CGEM's Depreciation & Amortization (CF) at $79000.0 in Q1 2026, $79000.0 in Q4 2025, and $79000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Cullinan Therapeutics | 1.37 Bn | 1.37 Bn | - | 79,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 79,000.00 |
| Mar 31, 2026 | 79,000.00 |
| Dec 31, 2025 | 79,000.00 |
| Sep 30, 2025 | 79,000.00 |
| Jun 30, 2025 | 77,000.00 |
| Mar 31, 2025 | 76,000.00 |
| Dec 31, 2024 | 77,000.00 |
| Sep 30, 2024 | 76,000.00 |
| Jun 30, 2024 | 77,000.00 |
| Mar 31, 2024 | 76,000.00 |
| Dec 31, 2023 | 77,000.00 |
| Sep 30, 2023 | 80,000.00 |
| Jun 30, 2023 | 81,000.00 |
| Mar 31, 2023 | 72,000.00 |
| Dec 31, 2022 | 59,000.00 |
| Sep 30, 2022 | 9,000.00 |
| Jun 30, 2022 | 12,000.00 |
| Mar 31, 2022 | 13,000.00 |
| Dec 31, 2021 | 12,000.00 |
| Sep 30, 2021 | 13,000.00 |